RxDoctor Payments Data

Teresa Deangelis, MD

Neurology · New York, NYNPI 1164463808

Payments from drug & device makers

$321,184in general payments, 2019–2025

Across 1,064 payments — averaging $301.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Adamas Pharmaceuticals, Inc.$119K
  • Biogen$81K
  • Novartis$58K
  • Roche Products Limited$21K
  • AstraZeneca$14K
  • Amgen$11K
  • plus $18K from 53 others

What the payments were for

  • Consulting fees$6,0696%
  • Speaking & faculty fees$74,12676%
  • Travel & lodging$5521%
  • Food & beverage$16,54517%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Adamas Pharmaceuticals, Inc.42$118,777
Biogen164$81,378
Novartis189$58,105
Roche Products Limited37$20,657
AstraZeneca(2 entities)52$13,658
Amgen(2 entities)90$10,739
EMD Serono, Inc.45$9,386
AbbVie121$2,063
TG Therapeutics, Inc.12$470
Teva Pharmaceuticals USA, Inc.23$457
Bristol Myers Squibb36$423
Takeda Pharmaceuticals U.S.A., Inc.14$416
Lundbeck LLC24$406
Acadia Pharmaceuticals Inc27$359
Argenx US, Inc.12$332
Pfizer17$313
Sanofi11$240
Grifols USA, LLC10$234
SK Life Science, Inc.10$227
Eisai Inc.8$222
Lilly USA, LLC12$215
Genentech USA, Inc.12$211
Neurocrine Biosciences, Inc.7$164
Johnson & Johnson7$158
Avanir Pharmaceuticals, Inc.6$148
MDD US Operations, LLC6$118
Otsuka America Pharmaceutical, Inc.5$108
Mallinckrodt Hospital Products Inc.5$97
UCB, Inc.4$91
Corium, LLC4$65
Biohaven Pharmaceutical Holding Company Ltd.3$64
Banner Life Sciences, LLC3$62
Catalyst Pharmaceuticals, Inc.3$58
CSL Behring2$50
Supernus Pharmaceuticals, Inc.3$49
Vanda Pharmaceuticals Inc.3$48
Impel Pharmaceuticals Inc.2$44
Amneal Pharmaceuticals LLC2$43
Akcea Therapeutics, Inc.3$42
Amylyx Pharmaceuticals, Inc.2$41
Tanabe Pharma America, Inc.2$40
Neuronetics, Inc.1$40
Vertical Pharmaceuticals, LLC2$35
Acorda Therapeutics, Inc2$31
Medtronic1$29
Sunovion Pharmaceuticals Inc.2$29
Livanova USA, Inc.2$27
GE HealthCare2$25
Axsome Therapeutics, Inc.1$25
Assertio Therapeutics, Inc.2$24
ANI Pharmaceuticals, Inc.1$23
Upsher-smith Laboratories LLC1$17
Mylan Specialty L.p.1$16
Kyowa Kirin, Inc.1$16
E.r. Squibb & Sons, L.L.C.1$15
Strongbridge US Inc.1$15
Ipsen Biopharmaceuticals, Inc1$15
Mallinckrodt Enterprises LLC1$14
Octapharma USA, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$321,184 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$202,926
Medicare patients
503
Services billed
1,842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate93$706,542
SolirisEculizumab12$637,542
TecfideraDimethyl Fumarate25$303,233
Kesimpta PenOfatumumab29$301,939
Avonex (4 Pack)Interferon Beta-1a20$222,761
Dimethyl Fumarate111$203,830
Glatiramer Acetate54$198,022
Avonex Pen (4 Pack)Interferon Beta-1a17$186,532
RebifInterferon Beta-1a/Albumin14$148,670
GlatopaGlatiramer Acetate36$136,036
AubagioTeriflunomide13$119,547
MayzentSiponimod11$106,164
Dalfampridine ErDalfampridine72$92,427
Nurtec OdtRimegepant Sulfate45$63,015
NuedextaDextromethorphan Hbr/Quinidine11$16,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$457$706,54293 claims
AstraZenecaSoliris$13,658$637,54212 claims
BiogenTecfidera, Avonex (4 Pack)$81,378$525,99445 claims
EMD Serono, Inc.Rebif$9,386$148,67014 claims
SanofiAubagio$240$119,54713 claims
NovartisMayzent$58,105$106,16411 claims
PfizerNurtec Odt$313$63,01545 claims
Avanir Pharmaceuticals, Inc.Nuedexta$148$16,41311 claims
Upsher-smith Laboratories LLCTopiramate$17$30814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →